Yong Ben

CIK: 0001967669

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (12.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)3 (37.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

BBOT

BridgeBio Oncology Therapeutics, Inc.

Officer

CRBP

Corbus Pharmaceuticals Holdings, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

BBOT
BridgeBio Oncology Therapeutics, Inc.
Oct 1, 2026
Tax Payment(F)
Direct
1K shares at avg. $3.94$4K
CRBP
Corbus Pharmaceuticals Holdings, Inc.
Sep 14, 2026
Sale(S)
Direct
2K shares at avg. $7.84$16K
BBOT
BridgeBio Oncology Therapeutics, Inc.
Jul 1, 2026
Tax Payment(F)
Direct
1K shares at avg. $7.80$8K
CRBP
Corbus Pharmaceuticals Holdings, Inc.
May 19, 2026
Award(A)
Direct
3.8K shares-
BBOT
BridgeBio Oncology Therapeutics, Inc.
Apr 1, 2026
Tax Payment(F)
Direct
1K shares at avg. $9.03$9K
BBOT
BridgeBio Oncology Therapeutics, Inc.
Mar 10, 2026
Award(A)
Direct
46.7K shares-
BBOT
BridgeBio Oncology Therapeutics, Inc.
Aug 26, 2025
Award(A)
Stock Option (Right to Buy)
Direct
357.2K shares-
CRBP
Corbus Pharmaceuticals Holdings, Inc.
May 30, 2025
Award(A)
Direct
4.8K shares-

		Type	Shares	Price		Ownership
Oct 1, 2026	BBOT BridgeBio Oncology Therapeutics, Inc.	Tax Payment(F)	1,047	$3.94	$4,125	Direct
Sep 14, 2026	CRBP Corbus Pharmaceuticals Holdings, Inc.	Sale(S)	2,000	$7.84	$15,683	Direct
Jul 1, 2026	BBOT BridgeBio Oncology Therapeutics, Inc.	Tax Payment(F)	1,047	$7.80	$8,167	Direct
May 19, 2026	CRBP Corbus Pharmaceuticals Holdings, Inc.	Award(A)	3,800	-	$0	Direct
Apr 1, 2026	BBOT BridgeBio Oncology Therapeutics, Inc.	Tax Payment(F)	1,047	$9.03	$9,454	Direct
Mar 10, 2026	BBOT BridgeBio Oncology Therapeutics, Inc.	Award(A)	46,670	-	$0	Direct
Aug 26, 2025	BBOT BridgeBio Oncology Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	357,177	-	-	Direct
May 30, 2025	CRBP Corbus Pharmaceuticals Holdings, Inc.	Award(A)	4,800	-	-	Direct

1-8 of 8 transactions

About Ben Yong

Ben Yong (SEC CIK 0001967669) files insider reports with the SEC as Chief Med & Dev Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT) and Director of Corbus Pharmaceuticals Holdings, Inc. (CRBP).

Signal8 holds 9 ownership filings by Ben Yong (1 Form 3, 8 Form 4), filed between Jun 2, 2025 and Oct 5, 2026. Those filings report 8 transactions, from May 30, 2025 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ben Yong's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Ben Yong

Oct 1, 2026: Tax withholding of BBOT shares (Form 4, code F).
Sep 14, 2026: Open-market sale of CRBP shares (Form 4, code S).
Jul 1, 2026: Tax withholding of BBOT shares (Form 4, code F).
May 19, 2026: Grant or award of CRBP shares (Form 4, code A).
Apr 1, 2026: Tax withholding of BBOT shares (Form 4, code F).

Other insiders filing for BridgeBio Oncology Therapeutics, Inc. (BBOT)

Cobo Marc, Principal Accounting Officer
Elmelech Idan, COO & Principal Financial Ofcr
Beltran Pedro, President and CEO
Chen Bihua, Director
Tipirneni Praveen P., Director
MCCORMICK FRANK, Director

How to read Form 4 transaction codes